BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...in the Phase III IMpassion131 study in triple-negative breast cancer.CStone’s PD-L1 mAb meets primary endpointCS1001 from CStone Pharmaceuticals Co. Ltd....
...III trial for first-line treatment of stage IV squamous and non-squamous non-small cell lung cancer. CStone...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...U.S. That excludes Greater China, where CStone Pharmaceuticals Co. Ltd. (HKEX:2616) has rights under a 2018 deal (see “CStone...
BioCentury | Mar 9, 2020
Finance

GenFleet eyes proof of concept with $50M series B

...Shanghai-based Yangtze River Pharmaceutical Group Co. Ltd. Lu has served as SVP of operations at CStone Pharmaceuticals Co. Ltd....
BioCentury | Mar 9, 2020
Finance

With $22M B round, Numab to build out multispecific mAb pipeline

...collaboration partner.” Numab also has a 2019 deal with CStone Pharmaceuticals Co. Ltd. (HKEX:2616), under which it granted CStone...
...to lead program ND021. The trispecific mAb targets PD-L1, 4-1BB and human serum albumin (see “CStone...
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...HKEX:1801); and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; NEEQ:833330). The chapter's other 2019 listings included CStone Pharmaceuticals Co. Ltd....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...and president of global policy and advocacy, will become CEO on Feb. 1. Oncology company CStone Pharmaceuticals Co. Ltd....
...she led the launch of Opdivo nivolumab, the first anti-PD-1 mAb to enter China’s market. CStone...
...Biosciences Inc. Circassia Pharmaceuticals plc Johnson & Johnson Janssen Pharmaceutical Research and Manufacturers of America (PhRMA) Bill & Melinda Gates Foundation CStone Pharmaceuticals Co. Ltd....
BioCentury | Sep 6, 2019
Product Development

Growing China’s capacity to conduct high-quality trials

...lung, breast, gastric or esophageal cancer. In the U.S. that number is 100-200, he said. CStone Pharmaceuticals Co. Ltd....
...can’t keep up with demand. “The clinical trial sites are overwhelmed.” Prior to joining Suzhou-based CStone...
...NMPA (formerly CFDA). The change has opened the door to faster expansion of trial networks. CStone’s...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...Phase I Founded: 2009 by Ye Tian and Shuixiong Cai University collaborators: N/A Corporate partners: CStone Pharmaceuticals Co. Ltd....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...SSE:ACE) 3/6/19 $23.9 $63.2 $50.0 -21% Kaleido Biosciences Inc. (NASDAQ:KLDO) 2/27/19 $75.0 $444.5 $345.8 -22% CStone Pharmaceuticals Co. Ltd....
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...partner them. At least one competing program has also been included in a U.S.-China deal. CStone Pharmaceuticals Co. Ltd....
...$346 million in milestones, plus royalties in a deal that included two other compounds (see "CStone...
Items per page:
1 - 10 of 57
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...in the Phase III IMpassion131 study in triple-negative breast cancer.CStone’s PD-L1 mAb meets primary endpointCS1001 from CStone Pharmaceuticals Co. Ltd....
...III trial for first-line treatment of stage IV squamous and non-squamous non-small cell lung cancer. CStone...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...U.S. That excludes Greater China, where CStone Pharmaceuticals Co. Ltd. (HKEX:2616) has rights under a 2018 deal (see “CStone...
BioCentury | Mar 9, 2020
Finance

GenFleet eyes proof of concept with $50M series B

...Shanghai-based Yangtze River Pharmaceutical Group Co. Ltd. Lu has served as SVP of operations at CStone Pharmaceuticals Co. Ltd....
BioCentury | Mar 9, 2020
Finance

With $22M B round, Numab to build out multispecific mAb pipeline

...collaboration partner.” Numab also has a 2019 deal with CStone Pharmaceuticals Co. Ltd. (HKEX:2616), under which it granted CStone...
...to lead program ND021. The trispecific mAb targets PD-L1, 4-1BB and human serum albumin (see “CStone...
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...HKEX:1801); and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; NEEQ:833330). The chapter's other 2019 listings included CStone Pharmaceuticals Co. Ltd....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...and president of global policy and advocacy, will become CEO on Feb. 1. Oncology company CStone Pharmaceuticals Co. Ltd....
...she led the launch of Opdivo nivolumab, the first anti-PD-1 mAb to enter China’s market. CStone...
...Biosciences Inc. Circassia Pharmaceuticals plc Johnson & Johnson Janssen Pharmaceutical Research and Manufacturers of America (PhRMA) Bill & Melinda Gates Foundation CStone Pharmaceuticals Co. Ltd....
BioCentury | Sep 6, 2019
Product Development

Growing China’s capacity to conduct high-quality trials

...lung, breast, gastric or esophageal cancer. In the U.S. that number is 100-200, he said. CStone Pharmaceuticals Co. Ltd....
...can’t keep up with demand. “The clinical trial sites are overwhelmed.” Prior to joining Suzhou-based CStone...
...NMPA (formerly CFDA). The change has opened the door to faster expansion of trial networks. CStone’s...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...Phase I Founded: 2009 by Ye Tian and Shuixiong Cai University collaborators: N/A Corporate partners: CStone Pharmaceuticals Co. Ltd....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...SSE:ACE) 3/6/19 $23.9 $63.2 $50.0 -21% Kaleido Biosciences Inc. (NASDAQ:KLDO) 2/27/19 $75.0 $444.5 $345.8 -22% CStone Pharmaceuticals Co. Ltd....
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...partner them. At least one competing program has also been included in a U.S.-China deal. CStone Pharmaceuticals Co. Ltd....
...$346 million in milestones, plus royalties in a deal that included two other compounds (see "CStone...
Items per page:
1 - 10 of 57